Table 1 The summary of studies of homoharringtonine-based regimens in the induction of acute myeloid leukemia
From: Homoharringtonine and omacetaxine for myeloid hematological malignancies
Reference | Regimen | Patients no. | CR, % | 3-year OS, % |
|---|---|---|---|---|
Huang 1989 [58] | Low dose HHT + low Ara-c | 16 | 75.0 | NP |
Zheng 1989 [12] | HHT + Ara-c | 34 | 70.6 | NP |
Bian 1993 [59] | HHT + Ara-c | 84 | 60.7 | 32 (5-year OS) |
Fu 2001 [60] | HHT + Ara-c | 41 | 73.1 | NP |
Yang 2005 [61] | HHT + Ara-c | 56 | 63.6 | NP |
Xue 1995 [62] | HHT + Ara-c + DNR | 50 | 86.0 | NP |
Xiao 2008 [63] | HHT + Ara-c + DNR | 72 | 86.1 | 55.9 |
Jin 2013 [67] | HHT + Ara-c + DNR | 198 | 67.0 | 48.0 |
Wan 1997 [64] | HHT + Ara-c + aclarubicin | 25 | 76.0 | NP |
Song 2011 [66] | HHT + Ara-c + aclarubicin | 150 | 81.0 | 45.0 |
Jin 2013 [67] | HHT + Ara-c + aclarubicin | 206 | 73.0 | 48.5 |